0
2020
Premenstrual Syndrome Treatment Market

Premenstrual Syndrome Treatment Market by Drug Type (Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026
Update Available On-Demand

A05965
Pages: 241
Jan 2020 | 3895 Views
Author(s) : Sayali Shinde , Onkar Sumant
Tables: 116
Charts: 61
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Premenstrual Syndrome Treatment Market

Request Now !

The global Premenstrual Syndrome Treatment Market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026. 

Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability.  

The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs. 

Premenstrual Syndrome Treatment Market

Get more information on this report : Request Sample Pages

For instance, according to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms and less than 10% are diagnosed with premenstrual dysphoric disorder (PMDD). Thus, increase in prevalence of PMS is anticipated to fuel the demand for drugs, thereby driving the premenstrual syndrome treatment market growth. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth. 

Premenstrual Syndrome Treatment Market Segmentation  

The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type it is classified as prescription and OTC.  According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).   

Segment Review 

Based on drug type, the premenstrual syndrome treatment market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment, and is estimated to show a significant market growth during the forecast period due to higher adoption of analgesics as first line treatment for the management of PMS. 
Analgesics drugs such as ibuprofen, acetaminophen, diclofenac, naproxen are widely used in management symptoms of PMS. These analgesics are generally used to reduce PMS symptoms such as stomach cramps, headache, muscle pain, joint pain and others. These drugs are available over the counter without a prescription but their overuse may cause adverse effects. 

Premenstrual Syndrome Treatment Market
By Drug Type

Your browser does not support the canvas element.

Analgesics is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Get more information on this report : Request Sample Pages

According to distribution channel, the premenstrual syndrome treatment is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs over traditional methods, increase in awareness of online providers, and rise in number of internet users.

Premenstrual Syndrome Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Drug Store and Retail Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Get more information on this report : Request Sample Pages

Asia-Pacific Premenstrual Syndrome Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the premenstrual syndrome treatment market, owing to the growth in awareness regarding premenstrual syndrome treatment, growth in healthcare awareness, and rise in adoption of premenstrual syndrome treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, surge in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Some other factors such as increase in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, due to high population base is expected to drive the growth of premenstrual syndrome treatment market in this region.  

Premenstrual Syndrome Treatment Market
By Geography

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 5.1% during 2019-2026.

Get more information on this report : Request Sample Pages

Get more information on this report : Request Sample Pages

The key players profiled in this report include ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and Shionogi Inc. 

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis of the premenstrual syndrome treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers the Premenstrual syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of all the four major geographical regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global Premenstrual syndrome treatment market growth.

Key Market Segments & Key Market Players

Segments Sub-segments
By Drug Type
  • Analgesics
  • Antidepressants
  • Oral Contraceptives & Ovarian Suppression Agents
  • Others

By Type
  • Prescription
  • OTC

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online pharmacies

By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players
  • ABBVIE INC.
  • AstraZeneca plc
  • BASF Corporation
  • Bayer AG.
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly And Company.
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • Shionogi Inc.
 

Loading Table Of Content...


 
 

Different form of drug such as analgesics, antidepressants, oral contraceptives, and ovarian suppression agents are used in the management of PMS.  The adoption of premenstrual syndrome therapeutics is expected to increase due to rise in the number of target population across the world and growth in awareness about premenstrual syndrome treatment in developing countries.

Ride in prevalence of PMS, increase in popularity of drug therapy, and surge in awareness regarding premenstrual syndrome treatment significantly boost the growth of the market. In addition, easy availability of drugs and unhealthy lifestyle can further support the market growth. However, unknown etiology of the disease is anticipated to hamper the market growth.

North America is expected to remain dominant during the forecast period, due to higher adoption of premenstrual syndrome treatment products, increased number of target population, presence of advanced healthcare facilities, easy availability of drugs, and early detection of this disease with higher health awareness among the general population drives the market growth. In addition, Asia-Pacific is expected to offer lucrative growth opportunities for the key market players during the forecast period, owing to rise in number of PMS affected population and awareness related to PMS.

Flash Sale
PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The market value of global premenstrual syndrome treatment market was $523.8 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global premenstrual syndrome treatment market in 2019 is $542.1 million.

A. The adoption of premenstrual syndrome treatment is expected to increase due to rise in awareness among the patient population, higher number of target population, rise in demand for PMS drugs and easy availability of the drugs significantly drives the market growth.

A. The base year calculated in the report is 2018.

A. Yes, AstraZeneca plc is profiled in the report.

A. Emerging countries of Asia-Pacific region are growing at a growth % of 5.1%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 5.0%, 6.1%, 4.2%, 5.7%, 4.5%, respectively.

A. The North America market held a major share in the premenstrual syndrome treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to higher prevalence of PMS, higher healthcare awareness, presence of well-developed healthcare infrastructure along with early detection of the disease, presence of trained medical professionals, and easy accessibility to the therapeutics are majorly driving the market growth in North Americ

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Premenstrual Syndrome Treatment Market

Start reading instantly.
This Report and over 13,000+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $4,904
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,483
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,995  $8,796
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers